High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer
EGFR tyrosine kinase inhibitor (TKI) therapy is approved for EGFR activating mutation positive patients with advanced NSCLC, but the standard for determining mutation status is with DNA derived directly from tumor tissue, which can be limited or not available. …